DiaMedica Therapeutics Inc. (DMAC)

Market Cap	284.86M
Revenue (ttm)	n/a
Net Income (ttm)	-31.93M
Shares Out	52.08M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	644,832
Open	5.91
Previous Close	6.31
Day's Range	5.26 - 6.10
52-Week Range	3.19 - 7.49
Beta	1.32
Analysts	Strong Buy
Price Target	12.33 (+125.41%)
Earnings Date	Nov 12, 2025

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the trea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: DMAC
• Website: https://www.diamedica.com

Analyst Summary

According to 3 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price target is $12.33, which is an increase of 125.41% from the latest price.

Price Target

$12.33

(125.41% upside)

Analyst Consensus: Strong Buy